The literature article entitled bone augmentation for revision total ankle arthroplasty with large bone defects.A technical note on 10 cases¿, by monika horisberger, et al, published in acta orthopaedica in 2015; was reviewed.The purpose of the article was to show how to perform revision taa in patients with substantial bone loss.The procedures described in the article were performed as a one stage or two stage revision.Two of the ten cases noted in the article were taa that were revised from an agility prosthesis (depuy).The indications for revision for all cases was aseptic loosening of the taa associated with extensive bone loss at the tibia, the talus, or both.In all cases preoperative diagnosis was posttraumatic osteoarthritis (oa).There were no intraoperative or postoperative complications.The two cases with agility prosthesis are noted below: at final follow-up, the tibial and talar components were radiographically stable.Patient 8: eight years until revision, one stage revision with bone augmentation of the tibia: 2x biocortical.
|
Depuy synthes is submitting this report pursuant to the provisions of 21 cfr, part 803.This report may be based on information which depuy synthes has not been able to investigate or verify prior to the required reporting date.This report does not reflect a conclusion by fda, depuy synthes or its employees that the report constitutes an admission that the device, depuy synthes, or its employees caused or contributed to the potential event described in this report.Additional narrative: product complaint #: (b)(4).Investigation summary no device associated with this report was received for examination.A worldwide lot specific complaint database search, or device history record (dhr) review, was not possible because the required lot number was not provided.Based on previous investigations, this complication of joint replacement is unlikely to have been the result of a device failing to meet required specifications.The information received will be retained for potential series investigations if triggered by trend analysis, post market surveillance, or other events within the quality system.If information is obtained that was not available for the initial medwatch, a follow-up medwatch, a follow-up medwatch will be filed as appropriate.
|